Covid-19 Intranasal Vaccine
Griffith University developed an intranasal COVID-19 vaccine, CDO-7N-1, offering long-term protection, stability at 4°C, and effectiveness against major variants. It is licensed for clinical trials by Indian Immunologicals Ltd.
Read original article
Griffith University has developed a next-generation intranasal COVID-19 vaccine, CDO-7N-1, which aims to provide a needle-free alternative for vaccination. This live attenuated vaccine is designed to be administered through the nasal passages, potentially inducing both mucosal and systemic immunity with a single dose. Research led by Professor Suresh Mahalingam indicates that the vaccine can offer long-term protection, with strong memory responses in the nasal mucosa lasting over a year. The vaccine is effective against all major variants of SARS-CoV-2 and has shown neutralizing capacity against SARS-CoV-1. It remains stable at 4°C for up to seven months, making it suitable for low- and middle-income countries. The vaccine has been licensed to Indian Immunologicals Ltd, which plans to advance it to clinical trials. The findings, published in Nature Communications, highlight the vaccine's potential to reduce transmission, prevent reinfection, and limit the emergence of new variants, marking a significant advancement in COVID-19 vaccination strategies.
- Griffith University has developed a needle-free intranasal COVID-19 vaccine, CDO-7N-1.
- The vaccine can provide long-term protection with a single dose and is effective against all major variants.
- It remains stable at 4°C for seven months, making it suitable for low- and middle-income countries.
- The vaccine has been licensed to Indian Immunologicals Ltd for further clinical trials.
- Research findings were published in Nature Communications, emphasizing the vaccine's potential to combat COVID-19 effectively.
Related
Combined Covid-flu vaccines are coming: Moderna jab clears major test
Moderna completes phase-III trials for a COVID-flu mRNA vaccine, showing higher efficacy in adults over 50. Plans for FDA approval highlight benefits of combination vaccines and mRNA technology's adaptability to variants.
We know why some people got Covid while others didn't
Researchers conducted a study exposing volunteers to SARS-CoV-2, revealing distinct infection groups and unique immune responses. Specific immune cell responses and a protective gene were identified, offering insights for future treatments and vaccine development.
World-first mRNA lung cancer vaccine trials launched in seven countries
Doctors have begun the first clinical trials for the mRNA lung cancer vaccine BNT116 in seven countries, targeting non-small cell lung cancer and aiming to improve patient survival rates.
Lung cancer vaccine trial begins in UK
A new lung cancer vaccine trial using mRNA technology has begun in the UK, involving 130 patients across seven countries. The BNT116 vaccine targets cancer cells, aiming to reduce side effects.
24 commentsThey make the claim so we'll have to see. I currently use a nitric oxide nasal spray as the nose is the major area to protect (and also use probiotic lozenges of the k12 strain for the throat).
--- “The vaccine offers potent protection against transmission, prevents reinfection and the spread of the virus, while also reducing the generation of new variants,” Dr Liu said.
“Unlike the mRNA vaccine which targets only the spike protein, CDO-7N-1 induces immunity to all major SARS-CoV-2 proteins and is highly effective against all major variants to date.
“Importantly, the vaccine remains stable at 4°C for seven months, making it ideal for low- and middle-income countries.” ---
> “Importantly, the vaccine remains stable at 4°C for seven months, making it ideal for low- and middle-income countries.”
This being a more traditional vaccine, I wonder if any vaccine hold outs will be more receptive
Given that X is the new name, should it not be "X formerly known as Twitter"?
Anything that gets snorted into your nose has a pretty short path to the brain, with potentially "interesting" results (cocaine, Naegleria fowleri etc.). So you have to be extra sure that your intranasal medication is harmless.
As the article mentions, this particular vaccine has been developed for four years. That seems to be long enough to be sure. But I wouldn't be taking it back in 2021 or 2022.
That's it's best feature, not the nasal administration IMO.
So, literally any amount of time?
Related
Combined Covid-flu vaccines are coming: Moderna jab clears major test
Moderna completes phase-III trials for a COVID-flu mRNA vaccine, showing higher efficacy in adults over 50. Plans for FDA approval highlight benefits of combination vaccines and mRNA technology's adaptability to variants.
We know why some people got Covid while others didn't
Researchers conducted a study exposing volunteers to SARS-CoV-2, revealing distinct infection groups and unique immune responses. Specific immune cell responses and a protective gene were identified, offering insights for future treatments and vaccine development.
World-first mRNA lung cancer vaccine trials launched in seven countries
Doctors have begun the first clinical trials for the mRNA lung cancer vaccine BNT116 in seven countries, targeting non-small cell lung cancer and aiming to improve patient survival rates.
Lung cancer vaccine trial begins in UK
A new lung cancer vaccine trial using mRNA technology has begun in the UK, involving 130 patients across seven countries. The BNT116 vaccine targets cancer cells, aiming to reduce side effects.